The Effects of r-metHuIFN-Gamma on the Lungs of Patients With AIDS
HIV Infections
About this trial
This is an interventional treatment trial for HIV Infections focused on measuring Pulmonary Alveoli, Macrophage Activation, Interferon-gamma, Recombinant, Injections, Subcutaneous, Aerosols, Acquired Immunodeficiency Syndrome
Eligibility Criteria
Inclusion Criteria Patients must have: Diagnosis of AIDS with one or more opportunistic infections. Kaposi's sarcoma with prior history of opportunistic infection. Stable dose of zidovudine (AZT) therapy. Preserved pulmonary, renal and hepatic function. Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: Presence of active infection. Active opportunistic infections. Cardiac disease. Central nervous system disorders. History of seizures. Irreversible airway disease. Patients with the following are excluded: Co-existing conditions and symptoms listed in Patient Exclusion Co-existing Conditions. Prior Medication: Excluded within 4 weeks of study entry: Immunosuppressive therapy. Cytotoxic therapy. Excluded: Interferon gamma therapy.
Sites / Locations
- New York Hosp - Cornell Med Ctr